Prion Like Spreading In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Prion-like spreading is a pathological mechanism in which misfolded proteins template the conversion of normally folded proteins in a self-propagating cascade. This process underlies disease progression in several neurodegenerative disorders, including Alzheimer's Disease (tau, amyloid-β), Parkinson's Disease (α-synuclein), ALS ([TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX--, SOD1), and Frontotemporal Dementia ([TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX--, tau. Unlike infectious prian diseases, the aggregates originate endogenously but share the fundamental property of templated misfolding and propagation between cells.
The key steps in prion-like spreading include:
See also: [Amyloid-Beta Aggregation], [Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- Pathology], [alpha-synuclein Aggregation], [TDP-43 Proteinopathy[/mechanisms/[tdp-43-proteinopathy[/mechanisms/[tdp-43-proteinopathy[/mechanisms/[tdp-43-proteinopathy--TEMP--/mechanisms)--FIX--
The fundamental mechanism involves:
Seed formation: A native, soluble protein (tau, α-synuclein, [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- undergoes initial misfolding, forming oligomeric seeds. This can be triggered by genetic mutations, post-translational modifications, environmental stressors, or stochastic events.
Templated conversion: Misfolded seeds act as templates that recruit and convert normally folded monomers into the pathological conformation. This follows nucleation-dependent polymerization kinetics, where seed formation is the rate-limiting step but once seeds are present, rapid elongation occurs (Jucker & Walker, 2013.
Fibril fragmentation: Large aggregates break into smaller fragments (secondary nucleation), generating new seeds that exponentially amplify the misfolded protein population (Rostami et al., 2025)).
Strain diversity: Different misfolded conformations (strains) of the same protein can template distinct aggregate structures with different biological properties—including different rates of propagation, cellular toxicity, and regional tropism. This explains the clinical heterogeneity of diseases involving the same protein (e.g., different tauopathies) (Fitzpatrick et al., 2017 (Fitzpatrick et al., 2017.
Prion-like proteins spread between cells through multiple mechanisms:
[Exosomes[/entities/[exosomes[/entities/[exosomes[/entities/[exosomes--TEMP--/entities)--FIX-- are 40-160 nm extracellular vesicles released by most cell types. Misfolded tau and [α-synuclein/proteins/alpha are packaged into exosomes and released into the extracellular space or directly transferred to recipient [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--. Exosomal tau has been shown to be more efficiently taken up and to seed aggregation more readily than free tau (Polanco et al., 2016; Rajendran et al., 2014). Blocking exosome secretion reduces tau spreading in vivo (Polanco et al., 2016).
TNTs are actin-based cytoplasmic bridges (50-700 nm diameter, up to several cell diameters in length) that connect distant cells and allow direct transfer of organelles, proteins, and other cargo between cells. Tau fibrils and α-synuclein aggregates transfer between [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- through TNTs, bypassing the extracellular environment (Abounit et al., 2016); Tardivel et al., 2016. TNT-mediated transfer may be particularly relevant for disease-specific regional patterns because it occurs along physical cell-cell connections (Abounit et al., 2016.
The most compelling evidence for trans-synaptic spread comes from circuit-based studies. Pathological tau and α-synuclein preferentially transfer across synapses, following established neural projections. This mechanism is supported by:
Misfolded protein seeds can enter cells through:
[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--. [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--, which contact millions of synapses, can transfer tau and α-synuclein via TNTs, potentially amplifying trans-synaptic spread across large brain regions (Rostami et al., 2025)).
Tau pathology in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- follows a highly stereotypical spatial progression described by Braak staging (Braak & Braak, 1991):
This progression follows the known cortico-cortical connectivity of the entorhinal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, with perforant pathway projections to the [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- and reciprocal connections to association cortices. Injection of tau PFFs into mouse entorhinal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- reproduces this spreading pattern experimentally.
In non-AD tauopathies, tau spreading follows different patterns reflecting different strains and neural vulnerabilities:
The Braak hypothesis for [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- proposes that α begins in the peripheral nervous system—specifically the enteric nervous system and olfactory bulb—and ascends to the central nervous system via the vagus nerve and olfactory pathways (Braak et al., 2003):
The gut-to-brain hypothesis is supported by evidence that vagotomy reduces PD risk, α-synuclein PFFs injected into the gut wall propagate to the brain in animal models, and GI symptoms precede motor onset by decades in many PD patients. However, a "brain-first" subtype has also been proposed, suggesting at least two distinct propagation origins (Borghammer & Van Den Berge, 2019.
[TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- pathology in [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- and [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- follows predictable spreading patterns:
Recent 2025 research using human neuron-like cells demonstrates that [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- fibrils are efficiently internalized and transferred from donor to receiver cells, with internalized fibrils recruiting endogenous [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- to form cytoplasmic neoaggregates, confirming the prion-like propagation hypothesis for [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- (Bhatt et al., 2025).
While [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- deposition is less stereotypical than tau spreading, [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- seeding has been demonstrated:
Injection of synthetic preformed fibrils (PFFs) into animal brains has become the standard method for studying prion-like spreading:
RT-QuIC (real-time quaking-induced conversion) and PMCA (protein misfolding cyclic amplification) assays can detect minute quantities of misfolded protein seeds in biospecimens. These techniques are now being applied clinically:
Cryo-electron microscopy has revealed the atomic structures of pathological filaments extracted from patient brains, demonstrating:
Despite mechanistic similarities, prion-like proteins in common neurodegenerative diseases differ from authentic prions (PrP^Sc) in several important ways (Meisl et al., 2025):
| Feature | True Prions (PrP^Sc) | Prion-like Proteins |
|---|---|---|
| Transmissibility between individuals | Yes (infectious) | Very rare/not documented naturally |
| Environmental persistence | High (resist sterilization) | Low |
| Zoonotic potential | Yes (BSE/vCJD) | No evidence |
| Rate of progression | Rapid (months to years) | Slow (years to decades) |
| Cell-type specificity | Moderate | High (strain-dependent) |
| Therapeutic targeting | Difficult | Active development |
The term "prion-like" acknowledges these differences while capturing the shared mechanism of templated protein misfolding and cell-to-cell propagation.
Understanding prion-like spreading opens several therapeutic strategies:
The study of Prion Like Spreading In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent 2025-2026 work on [prion-like spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading--TEMP--/mechanisms)--FIX-- emphasizes convergent seeded-aggregation mechanisms across [prion protein[/proteins/[prion-protein[/proteins/[prion-protein[/proteins/[prion-protein--TEMP--/proteins)--FIX-- and [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- pathobiology.
A critical distinction in understanding protein aggregation in neurodegenerative diseases is whether observed propagation reflects intercellular templated spread (prion-like transmission) or parallel cell-autonomous degeneration. This question remains incompletely resolved.
Evidence for Intercellular Templated Spread:
Evidence for Cell-Autonomous Vulnerability:
Key Unresolved Questions:
Primary Initiation: What triggers the initial misfolding event in susceptible [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--? Is it cell-autonomous proteostatic failure or exposure to external seeds?
Propagation Mechanism: Do seeds travel extracellularly, trans-synaptically, or within neurons to reach target cells? The relative importance of each pathway is unclear.
Strain Variation: Do different protein conformers (strains) exhibit varying propagation capacities? How does strain diversity affect disease phenotype?
Therapeutic Implications: If templated spread is primary, anti-seed antibodies or seed inhibitors could be disease-modifying. If cell-autonomous mechanisms dominate, interventions targeting proteostasis, energy metabolism, or cellular stress responses may be more effective.
Data Types Needed to Establish Causality in Humans:
The current evidence supports both mechanisms operating simultaneously, with their relative contribution likely varying by disease stage, protein type, and individual patient factors.
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 20 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 49%